TuHURA Biosciences Discovers Delta Opioid Receptor Target for Advanced Cancer Immunotherapy

Breakthrough in Cancer Immunotherapy: TuHURA Biosciences Targets Delta Opioid Receptor

TuHURA Biosciences, Inc. is making significant progress in the field of cancer immunotherapy with its recent discovery regarding the Delta Opioid Receptor (DOR). For the first time, researchers confirm that DOR is expressed on tumor-associated myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). This revelation is pivotal as it suggests that inhibiting DOR could reprogram the immunosuppressive mechanisms of these cells, offering a potential pathway to overcome acquired resistance to existing cancer therapies. The findings, which are set to be presented at the 67th American Society of Hematology Annual Meeting in December 2025, underscore the importance of DOR as a target for pharmacological intervention in cancer treatment.

The collaborative research conducted by scientists at TuHURA and The Moffitt Cancer Center emphasizes DOR's role in restoring stem cell proliferation, particularly in patients with myeloid dysplastic syndrome (MDS). The results indicate that DOR is integral to regulating inflammation and autoimmunity within the tumor microenvironment. Dr. James Bianco, CEO of TuHURA, expresses optimism about the implications of this research, highlighting that targeting DOR could lead to the development of a new class of immune-modulating therapies. By combining selective DOR inhibitors with a VISTA-inhibiting antibody, TuHURA aims to create innovative antibody-drug conjugates (ADCs) that could enhance the efficacy of cancer treatments.

This research marks a pivotal advancement in understanding the mechanisms behind cancer immunotherapy resistance. By focusing on DOR, TuHURA Biosciences demonstrates its commitment to pioneering novel strategies that could significantly improve patient outcomes. As the scientific community prepares for the upcoming presentation, the anticipation builds around how these findings could reshape approaches to treating various cancers, especially for patients who have not responded to traditional therapies.

In addition to the focus on DOR, TuHURA's research aligns with broader trends in cancer treatment, where the emphasis is increasingly on personalized medicine and targeted therapies. The company's innovative strategies could play a crucial role in addressing the challenges posed by tumor heterogeneity and the complex immune landscape of cancers. As the December presentation approaches, the implications of this work may resonate throughout the oncology community, potentially setting new standards for future cancer therapies.